Ranbaxy Reports Quarterly Loss Ahead of Sun Pharma Deal
This article is for subscribers only.
Ranbaxy Laboratories Ltd., the drugmaker being acquired by Sun Pharmaceutical Industries Ltd., posted a quarterly loss after finance costs rose and the U.S. banned imports from its Punjab factory.
Gurgaon-based Ranbaxy reported a loss of 736.5 million rupees ($12.3 million) in the three months ended March compared with a profit of 1.26 billion rupees a year earlier, according to a company statement to the stock exchange today.